

Disclosures

Relevant Disclosures:

The Menopause Society Board of Directors

Consultant: Astellas

No conflicts of interest

References:

I will discuss clinical studies of off label use of pharmaceuticals for vasomotor symptoms.

This presentation references people born with ovaries. I may use the terms women, she, and her. These terms may not capture the diversity of all those experiencing menopause. We need more research to explore how diverse people experience menopause.

2












Vasomotor Symptoms (VMS) - Mild: sensation of heat without sweating - Moderate: sensation of heat with sweating, able to continue activity - Severe: sensation of heat with sweating, causing cessation of activity. - Severe: sensation of heat with sweating, causing cessation of activity.



	f Hot Flashes	
Shorter	Longer	Median Years
Postmenopause with symptom onset	Pre/perimenenopause at symptom onset	3.4 v 11.8
Japanese/Chinese	African American race	4.8/5.4 vs 10.1
Non-Hispanic White	Hispanic	6.5 v 8.9
Education≥College	Education < College	7.7 v 9.9
Stress never/almost never	Stress at least sometimes	8.9 v 10.8
No depression	Depression	7.7 v 11.0
No anxiety	Anxiety (mild-severe)	5.0 v 7.4
	Financial strain	
	Poor social support	
	Obesity	
	Smoking	
	Single	

Treatment Options

Hormone

Estrogen

• Estrogen + Progesterone

• Estrogen + SERM


Non-hormone

• Pharmaceutical therapies

• Behavioral and lifestyle changes

• Dietary supplements

11



Non-Oral Estrogen Therapy



- Transdermal/Topical/Vaginal
 Patch, gel, spray, and emulsion
 Avoids first-pass hepatic metabolism
 - More stable serum levels
 - \bullet Minimal effect on SHBG; minimized
 - negative impact to sexual function
 Reduced risk of VTE/stroke compared to oral ET in observational studies



13



14

Types of Progestogen Therapy

- Micronized Progesterone
 Compound identical to endogenous progesterone
 Prometrium is the only FDA-approved bioidentical progestogen
 Contraindicated in women with peanut allergy
 - Bedtime dosing advised because of sedating effects

- Progestin
 Synthetic products with progesterone-like activity
 Medroxyprogesterone acetate (MPA) is the most commonly used and studied in the United States for endometrial protection

Schussler P, et al. Psychoneuroendorinology. 2008;33(8):1124-1131. Montplaisir J, et al. Menopause. 2001;8(1):10-18

Methods of EPT Administration

Continuous-cyclic (sequential)

- Daily estrogen with progestogen added cyclically for 12-14 d each month
 80% of women will experience bleeding with progestogen withdrawal

Continuous-combined

- Daily estrogen and progestogen
 Low rates of endometrial hyperplasia
 Higher rates of amenorrhea
 Decreased breakthrough bleeding after 2 yrs

ger B, et al. Obstef Gynecol. 1994;83(5pt1):993-700; Ettinger B, et al. Obstef Gynecol. 2001;98(2):205-211; Odmark IS, et al. Menopause. 2005;12(6):699-707 Fer RZ, et al. Obstef Gynecol. 2007;10(6):581-587. Pempro [pockage insert]. Philadelphia, PA: Wyeth; 2009. Furness S, et al. Ochrane Database Syst Rev. (S)(5)(2000)402. Caper FF; et al. J. Soc. Synecol Investig. 1996;65(5):252-234.

16

Alternative Progestogen Options

- · Levonorgestrel-containing IUD
- May provide endometrial cancer protection
- Off label
- Long-term efficacy data is needed

17

ET Combined With an Estrogen Agonist/Antagonist

- Tissue-selective estrogen complex (TSEC)
- Daily estrogen combined with a daily selective estrogen-receptor modulator (SERM)
- Approved for treatment of VMS and prevention of osteoporosis
- Amenorrhea rates similar to placebo
- Safety profile comparable to placebo

Archer DF, et al. Furlii Steril. 2009;92(3):1039-1044. Pinkerton JV, et al. Obstet Gynecol. 2013;121(5):959-968. Pinkerton JV, et al. J Clin Endocrinol Metab. 2014;99(2):E189-E198. Pickar JH, et al. Menopause. 2018;25(9):1033-1045.

Transdermal Hormone	Therapy
---------------------	---------

Medications	Available doses*
Transdermal estrogen formulatio monly prescribed in the United S	ns for menopausal hormone therapy com itates
Weekly estradiol patch	0.014 mg, 0.025 mg, 0.0375 mg, 0.05 mg, 0.06 mg, 0.075, 0.1 mg
	Standard: 0.0375-0.05 mg
	Low: 0.025 mg
	Ultra-low: 0.014 mg
Twice weekly estradiol patc	0.025 mg, 0.0375 mg, 0.05 mg, 0.075 mg, 0.1 mg
	Standard: 0.0375-0.05 mg
Combination transdermal estrog	en-progestin formulations available*
Estrogen	Progestin
Estradiol 0.05 mg	Norethindrone 0.14 mg, 0.25 mg
Estradiol 0.045 mg	Levonorgestrel 0.015 mg

Oral Hormone Therapy

Medications	Available doses
Oral estrogen formulations for menopausal hormone therapy commonly prescribed in the United	
Estradiol	0.5 mg, 1.0 mg, 2.0 mg
	Standard: 1.0 mg
	Low: 0.5 mg
Conjugated equine estrogen	0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg
	Standard: 0.625 mg
	Low: 0.3 mg, 0.45 mg
Combination oral estrogen-progestogen formulations available	
Estradiol (0.5 mg, 1.0 mg)	Drospirenone (0.25 mg, 0.5 mg)
Estradiol (0.5 mg, 1.0 mg)	Norethindrone acetate (0.1 mg, 0.5 mg)
Estradiol (1.0 mg)	Norgestimate (0.09 mg)
Estradiol (1.0 mg)*	Progesterone (100 mg)*
Ethinyl estradiol (2.5 µg, 5 µg)	Norethindrone acetate (0.5 mg, 1.0 mg)
Conjugated equine estrogen (0.3 mg, 0.45 mg, 0.625 mg)	Medroxyprogesterone acetate (1.5 mg, 2.5 mg, 5 mg)
Oral progestogen formulations for menopausal hormone therapy commonly prescribed in the U	
Medroxyprogesterone acetate	2.5 mg, 5 mg, 10 mg
Progesterone*	100 mg, 200 mg

20

Non-Hormone Prescription Therapies for VMS

- FDA-approved prescription treatments
 Paroxetine 7.5 mg daily
 Fezolinetant 45 mg daily
 Off-label prescription therapies
 Selective serotonin reuptake inhibitors
 Serotonin-norepinephrine reuptake inhibitors
 Gabapentin
 Oxybutynin

ı	Non-Hormone	Pharmaceuticals
Fezolinetant	45 mg daily	Single dose, no titration needed
Selective Serotonin Reuptake Inhibitors		
Paroxetine salt	7.5 mg	Single dose, no titration needed
Paroxetine	10-25 mg/d	Start with 10 mg/d
Citalopram	10-20 mg/d	Start with 10 mg/d
Escitalopram	10-20 mg/d	Start with 10 mg/d (for sensitive or older
	-	women, start with 5 mg/d for titration, but this
		dose has not been evaluated for efficacy)
Serotonin Norepinephrine Reuptake Inhibitors		
Desvenlafaxine	100-150 mg/d	Start with 25-50 mg/d and titrate up by that
	_	amount each day
Venlafaxine	37.5-150 mg/d	Start with 37.5 mg/d
Gabapentin	900-2,400 mg/d	Start with 100-300 mg at night, then add 300
		mg at night, then a separate dose of 300 mg
		in the morning (start 100 mg if concerned
		about sensitivity)
Oxybutynin	2.5-5 mg mg/d	Start with 2.5 mg daily and increase to 5 mg
	1	twice daily after one week

-	-

NON-HORMONES: RECOMMENDED

- Cognitive-behavioral therapy (Level I)
- Clinical hypnosis (Level I)
- Fezolinetant (Level I)
- Selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (Level I)
- Gabapentin (Level I)
- Oxybutynin (Levels I-II)
- Weight loss (Levels II-III)
- Stellate ganglion block (Levels II-III)

Level I: Good and consistent scientific evidence.
Level II: Limited or inconsistent scientific evidence.
Level III: Consensus and expert opinion.

23

NON-HORMONES: NOT RECOMMENDED

- Paced respiration (Level I)
- Supplements/Herbal remedies (Levels I-II)
- Cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation (Level II)
- Soy foods and soy extracts, soy metabolite equol (Level II)
- Cannabinoids (Level II)
- Chiropractic interventions and acupuncture (Levels I-III)
- Clonidine (Levels I-III)
- Dietary modification (Level III)
- Pregabalin (Level III)


Level I: Good and consistent scientific evidence.

Level II: Limited or inconsistent scientific evidence.

Level III: Consensus and expert opinion.



















32

NON-HORMONES: NOT RECOMMENDED

- Paced respiration (Level I)
- Supplements/Herbal remedies (Levels I-II)
- Cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation (Level II)
- Soy foods and soy extracts, soy metabolite equol (Level II)
- Cannabinoids (Level II)
- Chiropractic interventions and acupuncture (Levels I-III)
- Clonidine (Levels I-III)
- Dietary modification (Level III)
- Pregabalin (Level III)

Level I: Good and consistent scientific evidence. Level II: Limited or inconsistent scientific evidence. Level III: Consensus and expert opinion.





Cultural Curiosity "I am sorry you've had such a challenging time with your symptoms. Everyone's experiences menopause symptoms differently. I would like to understand more about your unique experience and your preference for natural treatment options..." Connected Care Connected Care Connected Care

Respectful Query

- How and what do you feel about going through menopause?
- What advice have you received about menopause?
- Are there any cultural practices related to menopause that are important for you to observe?
- Do you have a spiritual, religious or faith practice that influences your health care?
- How do you manage your menopausal symptoms? Foods, herbs, behaviors?
- We all want to live our best lives. Are there things that get in the way of you taking care of yourself and living your best life?



37

Connected Care

"Elise, I like to be sure that all of my patients receive information about all available and effective treatment options. You may not be interested in some of them, but I want to be sure that you have complete information before making a decision. Are you ok with me reviewing non-natural therapies?"



38

